Study: NCT02587598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB053914
Description: Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-DAC (Intermediate dose cytarabine)
Description: Cytarabine dose will be 1 g/m\^2. Cytarabine will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine dose will be 75 mg/m\^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.